PharmaSens Welcomes New Board Members
PharmaSens, a pioneering developer of advanced insulin patch pumps for individuals with diabetes, has announced the exciting appointment of Robert A. Gabbay, MD, PhD, FACP, and James L. Peterson to its board of directors. This strategic move positions the company firmly on its path to delivering cutting-edge solutions in diabetes care, including a novel wearable patch device that merges insulin delivery with continuous glucose monitoring.
Strengthening Clinical Research and Development
Jean Patricot, the chairman of the PharmaSens board, expressed enthusiasm about the new appointments, stating, "Welcoming Dr. Gabbay and James Peterson to our board is a great honor and represents a significant milestone for PharmaSens as the company delves deeper into clinical research. Their wealth of knowledge will enhance our efforts in simplifying diabetes management and widening access to insulin pump therapy for diabetic patients worldwide."
Dr. Robert Gabbay's Experience
Dr. Gabbay brings a wealth of experience to the table, having recently served as the chief scientific and medical officer of the American Diabetes Association. In this role, he concentrated on advancing research and treatment strategies for diabetes. His extensive career spans over 40 years, during which he has been recognized as a leader in patient care, research, and education within the diabetes field.
Academic and Professional Background
Throughout his distinguished career, Dr. Gabbay has held substantial positions, including associate professor of medicine at Harvard Medical School. He honed his skills as an endocrinologist at the prestigious Joslin Diabetes Center and has been involved in critical research aimed at improving healthcare delivery systems for diabetes patients.
James Peterson's Executive Leadership Skills
James Peterson's arrival to the PharmaSens board is equally significant. With an extensive background in executive leadership, mergers and acquisitions, and corporate growth strategies, Peterson has spent over two decades at Haemonetics, where he ascended to the role of president and CEO. His experience does not stop there; he has also served as an executive investor in diabetes technologies and has founded insulin delivery companies, contributing greatly to the advancement of this vital healthcare sector.
Past Contributions
In addition to his entrepreneurial success, Peterson has been actively engaged with organizations like the American Diabetes Association and the Joslin Diabetes Center, where he has had a lasting impact on strategic finance and governance.
Future Aspirations for PharmaSens
As PharmaSens embarks on its next chapter, the leadership of Dr. Gabbay and Mr. Peterson is poised to guide the organization towards innovative solutions that can response effectively to the rising demand for diabetes care. Marcel Both, CEO of PharmaSens, indicated optimism regarding their contributions, stating, "Their depth of experience in clinical and entrepreneurial sectors will be instrumental in our ongoing development efforts."
Educational Qualifications
Dr. Gabbay earned his medical degree from the State University of New York at Brooklyn and holds a PhD in biochemistry from the University of Wisconsin, along with a BS in biochemistry from McGill University. He is board certified in both internal medicine and endocrinology. Meanwhile, Peterson possesses an MBA from Stanford University’s Graduate School of Business and a BS in bioengineering from the University of Washington.
About PharmaSens
PharmaSens AG is committed to revolutionizing diabetes management through innovative medical technologies. With a focus on broadening the accessibility of insulin pump therapy, the PharmaSens team leverages extensive expertise in diabetes care and device engineering, having significantly contributed to developing several generations of insulin pumps. Over years of dedicated research and innovative action, PharmaSens has secured a portfolio of patented products aimed at improving patient outcomes and experiences.
Frequently Asked Questions
What is PharmaSens known for?
PharmaSens is known for developing innovative insulin patch pumps designed to improve diabetes management.
Who are the new board members at PharmaSens?
The new board members are Robert A. Gabbay, MD, and James L. Peterson, who bring extensive experience in diabetes care and entrepreneurship.
How will the new board members impact PharmaSens?
They will enhance PharmaSens's clinical research and development efforts, helping the company deliver cutting-edge diabetes care solutions.
What is the goal of PharmaSens's technology?
PharmaSens aims to combine insulin delivery with continuous glucose monitoring in a single wearable device for convenient diabetes management.
What is PharmaSens's vision for the future?
PharmaSens envisions expanding access to insulin pump therapy and innovating the way diabetes care is managed globally.
